Sonoma Pharmaceuticals' Q1 revenue rises 18%

Sonoma Pharmaceuticals

07/08/2025 21:25

Overview

Sonoma fiscal Q1 revenue rises 18% yr/yr, missing analyst expectations

U.S. revenue increases 57% due to higher health care product sales

Net loss per share for fiscal Q1 decreased 43% yr/yr

Result Drivers

U.S. REVENUE GROWTH - 57% increase in U.S. revenue driven by higher sales of human and animal health care products

STRATEGIC INITIATIVES - Expansion of consumer-focused product portfolio and regulatory approvals contributed to revenue growth

LATIN AMERICA DECLINE - Revenue decreased due to timing of customer orders for overflow manufacturing

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$4 mln
$4.05 mln (1 Analyst)
Q1 Gross Profit
$1.50 mln
Q1 Operating Expenses
$2.60 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 79.6% above its August 6 closing price of $3.02

Press Release: ID:nACSglzl8a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)